A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …
CRISPR-Cas9 technology, a powerful tool for gene editing, has made significant strides in therapeutic applications, especially within the central nervous system (CNS). A recent study highlights the potential of non-viral delivery of CRISPR-Cas9 ribonucleoproteins (RNPs) into the mouse striatum, offering a promising alternative to viral vector-based delivery. Highlights: Non-Viral Delivery of CRISPR-Cas9: The study focuses …
In the quest to understand the intricate relationship between our diet, brain, and behavior, scientists are turning their focus to a unique receptor, GPR120. This protein, known for interacting with long-chain fatty acids like omega-3s, is shedding new light on how our body’s inflammation and metabolism can directly affect our mental health. By exploring GPR120’s …
Alzheimer’s disease, a debilitating neurodegenerative condition, is influenced significantly by a blend of genetic, environmental, and lifestyle factors. New research focuses on environmental risk factors and microglia (the brain’s immune cells) for Alzheimer’s development. Highlights: Alzheimer’s Disease and Microglia: Alzheimer’s is characterized by cognitive decline, and microglia play a crucial role in its pathogenesis, acting …